REMOTE AF-2

  • Research type

    Research Study

  • Full title

    REMOTE AF-2: Precision detection and prediction of atrial arrhythmias using artificial intelligence and consumer wearable devices.

  • IRAS ID

    354811

  • Contact name

    Shouvik Haldar

  • Contact email

    s.haldar@rbht.nhs.uk

  • Sponsor organisation

    Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    An irregular heart rhythm known as Atrial Fibrillation (AF) affects tens of millions of people around the world, and this burden continues to grow as the global population ages. AF reduces patients' quality of life and can lead to heart failure and stroke.

    The REMOTE AF 2 study aims to improve patient care by using wearable devices and artificial intelligence to predict and detect the AF in an at-risk population. At present, AF can be detected in several ways, requiring significant clinician time. Electrocardiograms (ECG) provide an electrical recording of the heart's rate and rhythm. They are accurate but only provide a 10-second recording at a single time point. Non-invasive ambulatory ECG monitors of varying lengths (24 hours to 14 days) provide intermittent analysis of heart rhythm, which is prone to missing AF episodes. Implantable monitoring devices offer long-term recording but require an invasive procedure and are expensive.

    Wearable technology, such as wrist-worn devices, offers a promising alternative for AF detection. They are relatively low cost, widely used, and if worn, provide reliable continuous monitoring of heart rate and rhythm We aim to develop a novel algorithm incorporating data from light sensor technology and additional information from wearables to increase the likelihood of detecting abnormal heart rhythms.

    This study significantly advances our proof-of-concept REMOTE-AF study, where we showed wearable device data had substantial potential to detect AF. REMOTE-AF-2 has the potential to transform patient care in an ‘at risk’, real-world patient population by enabling cost-effective, continuous monitoring in a group of patients where early identification of AF is crucial to prevent deterioration in health.

  • REC name

    North East - Newcastle & North Tyneside 2 Research Ethics Committee

  • REC reference

    25/NE/0106

  • Date of REC Opinion

    2 Jul 2025

  • REC opinion

    Further Information Favourable Opinion